These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31981999)

  • 1. Drugging histone methyltransferases in cancer.
    Richart L; Margueron R
    Curr Opin Chem Biol; 2020 Jun; 56():51-62. PubMed ID: 31981999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting EZH2 as cancer therapy.
    Hanaki S; Shimada M
    J Biochem; 2021 Sep; 170(1):1-4. PubMed ID: 33479735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Covalent inhibitors of EZH2: Design, synthesis and evaluation.
    Zhang Q; Chen X; Hu X; Duan X; Wan G; Li L; Feng Q; Zhang Y; Wang N; Yu L
    Biomed Pharmacother; 2022 Mar; 147():112617. PubMed ID: 34998031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
    Morera L; Lübbert M; Jung M
    Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas.
    Zhou B; Liang X; Mei H; Qi S; Jiang Z; Wang A; Zou F; Liu Q; Liu J; Wang W; Hu C; Chen Y; Wang Z; Wang B; Wang L; Liu J; Liu Q
    J Med Chem; 2021 Oct; 64(20):15170-15188. PubMed ID: 34664960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects.
    Xia J; Li J; Tian L; Ren X; Liu C; Liang C
    J Med Chem; 2022 May; 65(10):7016-7043. PubMed ID: 35531606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the EZH2 histone methyltransferase as a therapeutic target in cancer.
    Italiano A
    Pharmacol Ther; 2016 Sep; 165():26-31. PubMed ID: 27179746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-target EZH2 inhibitor: latest advances in medicinal chemistry.
    Wei L; Mei D; Hu S; Du S
    Future Med Chem; 2024 Aug; 16(15):1561-1582. PubMed ID: 39082677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, Synthesis, and Biological Evaluation of a Potent Dual EZH2-BRD4 Inhibitor for the Treatment of Some Solid Tumors.
    Huang N; Liao P; Zuo Y; Zhang L; Jiang R
    J Med Chem; 2023 Feb; 66(4):2646-2662. PubMed ID: 36774555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity.
    Bate-Eya LT; Gierman HJ; Ebus ME; Koster J; Caron HN; Versteeg R; Dolman MEM; Molenaar JJ
    Eur J Cancer; 2017 Apr; 75():63-72. PubMed ID: 28214660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting histone methyltransferase EZH2 as cancer treatment.
    Kondo Y
    J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review.
    Rugo HS; Jacobs I; Sharma S; Scappaticci F; Paul TA; Jensen-Pergakes K; Malouf GG
    Adv Ther; 2020 Jul; 37(7):3059-3082. PubMed ID: 32445185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repositioning of Difluorinated Propanediones as Inhibitors of Histone Methyltransferases and their Biological Evaluation in Human Leukemic Cell Lines.
    Pal T; Sharda A; Khade B; Ramaa CS; Gupta S
    Anticancer Agents Med Chem; 2018; 18(13):1892-1899. PubMed ID: 29623853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recently discovered EZH2 and EHMT2 (G9a) inhibitors.
    Soumyanarayanan U; Dymock BW
    Future Med Chem; 2016 Sep; 8(13):1635-54. PubMed ID: 27548656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance.
    Brooun A; Gajiwala KS; Deng YL; Liu W; Bolaños B; Bingham P; He YA; Diehl W; Grable N; Kung PP; Sutton S; Maegley KA; Yu X; Stewart AE
    Nat Commun; 2016 Apr; 7():11384. PubMed ID: 27122193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas.
    Vaswani RG; Gehling VS; Dakin LA; Cook AS; Nasveschuk CG; Duplessis M; Iyer P; Balasubramanian S; Zhao F; Good AC; Campbell R; Lee C; Cantone N; Cummings RT; Normant E; Bellon SF; Albrecht BK; Harmange JC; Trojer P; Audia JE; Zhang Y; Justin N; Chen S; Wilson JR; Gamblin SJ
    J Med Chem; 2016 Nov; 59(21):9928-9941. PubMed ID: 27739677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancer of zeste homolog 2 (EZH2) inhibitors.
    Gulati N; Béguelin W; Giulino-Roth L
    Leuk Lymphoma; 2018 Jul; 59(7):1574-1585. PubMed ID: 29473431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone methyltransferase inhibitors: novel epigenetic agents for cancer treatment.
    Zagni C; Chiacchio U; Rescifina A
    Curr Med Chem; 2013; 20(2):167-85. PubMed ID: 23210854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
    Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2 inhibitors: a patent review (2014-2016).
    Stazi G; Zwergel C; Mai A; Valente S
    Expert Opin Ther Pat; 2017 Jul; 27(7):797-813. PubMed ID: 28394193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.